3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Unknown
2
Completed
1
Sponsor Class
OTHER
2
OTHER_GOV
1
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Urinary Bladder Neoplasms
3
Recurrence
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
BCG Connaught
×
Genitourinary
×
Clear all
NCT02948543
2023-06-18
BCG+MM
University of Sydney
Phase 3
Unknown
501 enrolled
NCT03664869
2021-04-01
FB10
Turku University Hospital
Phase 3
Unknown
300 enrolled
NCT01442519
2011-09-28
BCG/EMDA-MMC
University of Rome Tor Vergata
Phase 3
Completed
212 enrolled